These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 19801149

  • 1. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
    Lorenzen JM, Neunhöffer H, David S, Kielstein JT, Haller H, Fliser D.
    Atherosclerosis; 2010 Mar; 209(1):184-8. PubMed ID: 19801149
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
    Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators.
    Circulation; 2004 Aug 31; 110(9):1103-7. PubMed ID: 15313950
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance.
    Chen M, Ichiki T, Ohtsubo H, Imayama I, Inanaga K, Miyazaki R, Sunagawa K.
    Hypertens Res; 2007 Oct 31; 30(10):971-8. PubMed ID: 18049030
    [Abstract] [Full Text] [Related]

  • 5. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
    van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW.
    J Hypertens; 2007 Dec 31; 25(12):2454-62. PubMed ID: 17984667
    [Abstract] [Full Text] [Related]

  • 6. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
    Mizukawa M, Ohmori K, Obayashi A, Ishihara Y, Yoshida J, Noma T, Yukiiri K, Kosaka H, Kohno M.
    Hypertens Res; 2009 Jul 31; 32(7):617-24. PubMed ID: 19461650
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct 31; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 9. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
    Mason RP.
    Vasc Health Risk Manag; 2011 Oct 31; 7():405-16. PubMed ID: 21796255
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
    Takai S, Miyazaki M.
    Am J Cardiovasc Drugs; 2006 Oct 31; 6(6):363-6. PubMed ID: 17192125
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
    Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M, Miyoshi K, Desilva VR, Higaki J.
    J Hum Hypertens; 2011 May 31; 25(5):334-9. PubMed ID: 20664555
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM, Omboni S, Barton J, Van Mieghem W, Narkiewicz K, Panzer PK, Puig JG, Stefanadis C, Zweiker R, Study Group.
    Blood Press Suppl; 2011 Apr 31; 1():3-11. PubMed ID: 21091270
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG, Chavanu KJ, Xu J.
    Am J Cardiovasc Drugs; 2009 Apr 31; 9(4):241-51. PubMed ID: 19655819
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.
    Lee TM, Lin MS, Chou TF, Chang NC.
    Am J Physiol Heart Circ Physiol; 2006 Sep 31; 291(3):H1281-9. PubMed ID: 16565312
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.